Il Dong Pharmaceutical Co Ltd (249420) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Il Dong Pharmaceutical Co Ltd stock KRW 8,365, price KRW 12,250, that is 31.7% below the price, quality 43 out of 100. Rating: overvalued. Calculated from audited financials with 24 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 6, 2026.
How to read this chart
60‑month range 10,431 KRW – 75,001 KRW · fair‑value band 5,698 KRW – 11,579 KRW · the 12,250 KRW price screens above the 8,365 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 3 fiscal years are left out: there the valuation rested on only a fraction of the usual models. As of Nov 6, 2026.
Follow Il Dong Pharmaceutical Co in your weekly email
Every Wednesday you see whether Il Dong Pharmaceutical Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Ildong Pharmaceutical Co., Ltd. develops, manufactures, and sells pharmaceutical products in South Korea.
Show moreShow less
The company offers active lactic acid bacterial and anti-diarrheal agents, antibiotics, antifungal and antiviral products, anti-cancer, antineoplastic agents, and NSAIDs and analgesics, as well as vitamins, minerals, and nutrients; and drugs for blood circulation, cardiovascular and central nervous system, dental, endocrine and metabolic system, gastrointestinal system, respiratory system, and urogenital system applications.
It also provides raw material drugs; health foods and foods; beverages; cosmetics; medical devices for scar treatment; and other drugs for treating thick wounds, osteoarthritis, periarthritis of shoulder, and artificial tears, as well as feminine cleanser products.
The company was founded in 1941 and is headquartered in Seoul, South Korea.
Stock analysis
Il Dong Pharmaceutical Co Ltd (249420) currently trades at 12,250 KRW, while our model-based Fair Value estimate is 8,365 KRW, 32% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of 15,958 KRW per share, and 8 of the 24 models we run sit above the 12,250 KRW price.
Bear case: the Growth DCF group reads lowest at 4,289 KRW, and 16 of the 24 models stay below the price. Data coverage for this calculation is medium.
Scenario range: 5,698 KRW (bear) to 11,579 KRW (bull), the price of 12,250 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 43/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is weak: less than 2 % a year.
Il Dong Pharmaceutical Co Ltd reported revenue of 567B KRW in FY2025 versus 560B KRW in FY2021, a compound +0.3%/yr. Reported net income was 27.7B KRW in FY2025.
Key figures
Market cap 386B KRW (≈ $285M) Micro · P/E ratio 8.7 · P/S ratio 0.66 · EPS (TTM) 1,384 KRW · Dividend yield 1.6% · Net margin 7.5% · Return on equity 18.5% · Return on assets (EBIT) −4.4% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 42 out of 100 (medium confidence).
What moves the price
The share trades about 72% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −32%, 249420 screens richer than that median.
Fair Value models
Bear5,698 KRWFair Value 8,365 KRWBull11,579 KRW
Price 12,250 KRW · Downside -31.7%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (1,015 KRW per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF3,818 KRW4,305 KRW4,847 KRW82
Growth DCF3,843 KRW4,289 KRW4,768 KRW80
Owner Earnings5,294 KRW6,172 KRW7,148 KRW78
All 24 models by family
DCF Models
FCF DCF3,818 KRW4,305 KRW4,847 KRW82
Owner Earnings5,294 KRW6,172 KRW7,148 KRW78
5Y Revenue Exit5,635 KRW7,787 KRW10,429 KRW73
5Y EBITDA Exit9,350 KRW14,268 KRW19,724 KRW75
5Y P/E Exit9,566 KRW14,646 KRW19,639 KRW71
10Y Revenue Exit4,641 KRW6,180 KRW8,058 KRW68
10Y EBITDA Exit6,703 KRW9,841 KRW13,673 KRW68
10Y P/E Exit6,817 KRW10,054 KRW13,622 KRW64
Earnings-Based
Graham-Dodd5,970 KRW12,500 KRW15,818 KRW66
PEG = 1.01,862 KRW2,660 KRW3,458 KRW57
EPV4,139 KRW4,394 KRW4,599 KRW74
Dividend Discount
Gordon GGM13.04 KRW17.48 KRW21.23 KRW69
DDM Multi-Stage13.04 KRW16.96 KRW20.56 KRW67
Multiples
P/E Multiple14,487 KRW19,316 KRW24,145 KRW63
P/S Multiple11,195 KRW14,926 KRW18,658 KRW58
P/B Multiple20,419 KRW27,225 KRW34,031 KRW55
EV/EBIT6,184 KRW8,814 KRW11,445 KRW65
EV/EBITDA12,315 KRW16,989 KRW21,663 KRW67
EV/Revenue3,925 KRW6,339 KRW8,753 KRW53
Asset-Based
NCAV (Graham)3,453 KRW4,627 KRW6,907 KRW54
Growth DCF
Growth DCF3,843 KRW4,289 KRW4,768 KRW80
Economic Profit
Residual Income6,432 KRW6,988 KRW7,904 KRW76
ROIC Compounder4,139 KRW4,394 KRW4,599 KRW72
Growth Earnings
Growth-Adj P/E10,597 KRW15,139 KRW19,681 KRW67
The fair value above starts from this blend and is adjusted for dilution from new shares.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.36/100
Revenue growth is weak: less than 2 % a year.
Revenue growth 1 year
−7.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−3.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.2%
Start year 2020 (pandemic)
Revenue growth 9 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.2%
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
1.2% (2020) → 3.4% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no profitable base year
not computed
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+74.3%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (South Korea: IMF forecast 2.1% a year to 2030, 2.1% from 2016 to 2025) that is about +70.8% a year for the price.
Compare Il Dong Pharmaceutical Co Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 549 stocks
Beats the industry median on 9/14 measures
Overall it ranks above its industry peers.
Valuation
Quality Score43 · Bottom 25%
Fair Value upside−31.7% · Below median
Profitability
Return on equity (12 months)18.5% · Top 25%
Return on assets4.8% · Above median
Net margin (12 months)7.5% · Below median
Operating margin (12 months)2.5% · Below median
Growth and dividend
Revenue growth (quarter YoY)6.8% · Above median
Dividend yield (12 months)1.6% · Above median
Balance sheet
Debt / equity0.01× · Below median
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Il Dong Pharmaceutical Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/249420
Frequently asked questions
Is Il Dong Pharmaceutical Co Ltd (249420) overvalued or undervalued?
As of Nov 6, 2026, our model estimates a fair value of 8,365 KRW versus a price of 12,250 KRW, about 32% lower (overvalued).
What is the fair value of 249420?
Our model-based fair value for Il Dong Pharmaceutical Co Ltd is 8,365 KRW (as of Nov 6, 2026), built from audited fundamentals. The current price: 12,250 KRW.
What is the quality score of 249420?
Il Dong Pharmaceutical Co Ltd has a Quality Score of 43/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Il Dong Pharmaceutical Co Ltd (249420)?
Our model-based price target is the fair value of 8,365 KRW (as of Nov 6, 2026) from 24 valuation models. Cautious scenario 5,698 KRW, optimistic scenario 11,579 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Il Dong Pharmaceutical Co Ltd stock forecast for 2026?
Our models put fair value at 8,365 KRW, about 32% lower versus a price of 12,250 KRW (overvalued). Cautious scenario 5,698 KRW, optimistic scenario 11,579 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Il Dong Pharmaceutical Co Ltd (249420)?
Il Dong Pharmaceutical Co Ltd reported trailing-twelve-month revenue of about 582B KRW (latest available figure, as of Nov 6, 2026).
Does Il Dong Pharmaceutical Co Ltd pay a dividend?
Il Dong Pharmaceutical Co Ltd currently shows a dividend yield of 1.63% relative to its recent price (as of Nov 6, 2026).
How much is the dividend of Il Dong Pharmaceutical Co Ltd (249420) and when is the ex-dividend date?
Il Dong Pharmaceutical Co Ltd pays a dividend of 200.00 KRW per share a year, a dividend yield of 1.6%. The last ex-dividend date was Mar 30, 2026. The payout ratio is 14.5% of earnings. Free cash flow covers the dividend 0.26 times. Our assessment: Watch coverage. The dividend isn’t fully covered by free cash flow or earnings, part of it is funded from reserves or debt. Fine for now, but worth watching: if it stays uncovered, the dividend could be cut.
What growth is priced into Il Dong Pharmaceutical Co Ltd (249420)?
For today's price to be fair in a discounted-cash-flow model, Il Dong Pharmaceutical Co Ltd would have to grow free cash flow by +74.3 % per year for five years (discount rate 12.8 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +0.2 % per year. As of Nov 6, 2026.
What discount rate (WACC) does the fair value of 249420 use?
Our models discount Il Dong Pharmaceutical Co Ltd at 12.8 %: a base by market capitalisation (micro), damped by beta 0.89, country premium for South Korea. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Il Dong Pharmaceutical Co Ltd that is +74.3 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (12.8 %) and the same formula as our fair value.
How much growth has Il Dong Pharmaceutical Co Ltd (249420) delivered so far?
Over the past 5 years revenue at Il Dong Pharmaceutical Co Ltd grew +0.2 % a year. The price currently implies free-cash-flow growth of +74.3 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Il Dong Pharmaceutical Co Ltd (249420) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Il Dong Pharmaceutical Co Ltd (+74.3 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Il Dong Pharmaceutical Co Ltd (249420)?
The free-cash-flow yield on the price is 0.42 %: that much free cash flow Il Dong Pharmaceutical Co Ltd produces per unit of market value. When it exceeds the discount rate of our models (12.8 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Il Dong Pharmaceutical Co Ltd (249420)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Il Dong Pharmaceutical Co Ltd it is 8,365 KRW per share (as of Nov 6, 2026), against a price of 12,250 KRW. It is the blended result of 24 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Il Dong Pharmaceutical Co Ltd stock overvalued or undervalued in 2026?
As of Nov 6, 2026, 249420 trades above its calculated fair value: price 12,250 KRW, fair value 8,365 KRW, a gap of about −32% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 249420?
No. The price is what the market pays today (12,250 KRW); the fair value is what the company's own numbers justify (8,365 KRW). For Il Dong Pharmaceutical Co Ltd the two are 3,885 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Il Dong Pharmaceutical Co Ltd worth?
The market values Il Dong Pharmaceutical Co Ltd at about 386B KRW (market capitalisation, as of Nov 6, 2026). Per share that is 12,250 KRW; our models calculate a fair value of 8,365 KRW per share.
What do the bullish and bearish scenarios say about 249420?
Our models span a range for Il Dong Pharmaceutical Co Ltd: cautious scenario 5,698 KRW, base 8,365 KRW, optimistic 11,579 KRW per share (as of Nov 6, 2026, price 12,250 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 249420?
Il Dong Pharmaceutical Co Ltd trades at a price-to-earnings ratio of 8.7 (as of Nov 6, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 8,365 KRW is built from several models across several years. Other multiples: P/B 1.6, P/S 0.7, EV/EBITDA 6.8.
How solid is the balance sheet of Il Dong Pharmaceutical Co Ltd (249420)?
Balance-sheet figures for Il Dong Pharmaceutical Co Ltd (as of Nov 6, 2026): return on equity 18.5%, debt of 0.01 per unit of equity. They feed the Quality Score of 43/100, which measures business quality independently of the share price.
How far is 249420 from its 52-week high?
Il Dong Pharmaceutical Co Ltd trades at 12,250 KRW, about 72% below its 52-week high of 44,007 KRW and at the low of 12,190 KRW (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 8,365 KRW is for.
Which stocks are comparable to Il Dong Pharmaceutical Co Ltd?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Il Dong Pharmaceutical Co Ltd stock attractive at the current price?
The data as of Nov 6, 2026: price 12,250 KRW, calculated fair value 8,365 KRW (−32%), Quality Score 43/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 249420 calculated?
We run Il Dong Pharmaceutical Co Ltd through 24 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 8,365 KRW builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Il Dong Pharmaceutical Co Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Il Dong Pharmaceutical Co Ltd (249420)?
The closing price on Nov 6, 2026 was 12,250 KRW. Our model-based fair value is 8,365 KRW, about 32% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Il Dong Pharmaceutical Co Ltd right now?
The price sits above even our optimistic bull case (11,579 KRW). The favourable scenario is already priced in. Weak quality (43/100) and above fair value at the same time, the margin of safety is missing on both counts. A fairly wide model range (5,698 KRW to 11,579 KRW) leaves room in how you read the outcome.
Key figures of Il Dong Pharmaceutical Co Ltd
How large is the market capitalisation of Il Dong Pharmaceutical Co Ltd (249420)?
The market capitalisation of Il Dong Pharmaceutical Co Ltd is 386B KRW (≈ $285M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Il Dong Pharmaceutical Co Ltd (249420)?
The price-to-sales ratio of Il Dong Pharmaceutical Co Ltd is 0.66 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Il Dong Pharmaceutical Co Ltd (249420)?
Earnings per share at Il Dong Pharmaceutical Co Ltd are 1,384 KRW (price ÷ EPS = P/E 8.7). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Il Dong Pharmaceutical Co Ltd (249420)?
The dividend yield of Il Dong Pharmaceutical Co Ltd is 1.6% (payout 14.5%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Il Dong Pharmaceutical Co Ltd (249420)?
The net margin of Il Dong Pharmaceutical Co Ltd is 7.5% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Il Dong Pharmaceutical Co Ltd (249420)?
The return on equity (ROE) of Il Dong Pharmaceutical Co Ltd is 18.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Il Dong Pharmaceutical Co Ltd (249420)?
On an EBIT basis the return on assets of Il Dong Pharmaceutical Co Ltd is −4.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Il Dong Pharmaceutical Co Ltd (249420)?
The operating margin of Il Dong Pharmaceutical Co Ltd is 2.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Il Dong Pharmaceutical Co Ltd (249420)?
Revenue at Il Dong Pharmaceutical Co Ltd is growing +6.8% versus a year earlier (3y avg −3.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Il Dong Pharmaceutical Co Ltd (249420)?
Earnings per share at Il Dong Pharmaceutical Co Ltd are growing +609% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Il Dong Pharmaceutical Co Ltd (249420) carry?
The net debt of Il Dong Pharmaceutical Co Ltd is 53.8B KRW (fiscal year 2025, ≈ 33.2 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Il Dong Pharmaceutical Co Ltd in the live analysis
One click puts Il Dong Pharmaceutical Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Some data
Nov 6, 2026